Lilly's Evolving Corporate Venture Model
By
Alex Lash / Email the Author / START-UP October 2010, Vol. 15, No. 9
Venture Round / Word Count: 1309 / Article # 2010900216
Executive Summary
Of all the big pharmaceutical companies, Eli Lilly & Co. has arguably been the most aggressive and creative in finding outsiders to help develop their drugs. With its latest venture, Lilly hopes to learn lessons from a past failed initiative. The Indianapolis drug firm is set to put up to $150 million to work, backing three traditional venture funds as part of a strategy that outsources development of its own molecules.
$85.00
Buy Now
For $85.00, purchase this 1309-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.